

SAHPRA Guideline Index

The following table has been adapted from the index published by SAPRA and updated as far as possible using information published on the SAHPRA website. October 2019.		Version	
Documents out for industry comment: 2.04; 2.11; 2.42; 2.45; 2.46; 2.48; 2.49; 2.50; 2.52; 2.53; 5.07; 7.04; 7.06; ZACH1.04; MDTD01 & 02; 8.01; 8.03; 8.04; 8.08; 8.09; 8.06; 6.1s; 7.04; 9.49; 9.65; 9.90; 9.92; 16.04;			
1 Guidelines and Forms			
1.01 Index to Guidelines and Forms			
2 Human Medicines			
2.01 General information			
2.02 Pharmaceutical and Analytical		V6 Jun11	Jun11
2.03 Alcohol content of medicines*		V1 Dec03	Dec03
2.04 Post-importation testing*		V1 Dec03	Dec03
2.05 Stability *		V7-1 Aug12	Aug12
2.06 Biostudies		V6 Jun15	Jul15
2.07 Dissolution*		V5 Jun15	Jul15
2.08 Amendments*		V6 Jul12	Aug12
2.09 Clinical		V1 Dec03	Dec03
2.10 Substitution of medicines		V2 Jun10	Apr10
2.11 Adverse Drug Reactions Reporting		V1-2	Dec12
2.12 Completing clinical trial applications (to be updated)			
2.13 Implementation of the post-registration amendments guideline		V1 Dec03	Dec03
2.14 Patient Information Leaflet (PIL)		V4 Dec13	Jan14
2.15 Proprietary names for medicines		V5 Nov14	Dec14
2.16 Package Inserts for human medicines		V5 Dec13	Dec13
2.17 Safety-related Package Insert Notifications (SR-PINs)		V3 Jun17	Aug17
2.20 Package Insert standardised texts		V4 Jun15	Jul15
2.21 ZA eCTD Module 1 Technical		V3 May19	May19



2.22 eCTD Validation Criteria	V2.1	Apr17
2.23 Submission in eCTD format	V2.1	Apr17
2.24 Guidance for the Submission of the ZA CTD / eCTD –	V1 May19	May19
2.25 Pharmaceutical & Analytical for CTD	V4 Aug14	Aug14
2.26 CTD Implementation Road Map	V6 Feb16	Feb16
2.27 eCTD Checksums	V2.1	Nov16
2.28 eCTD Questions & Answers	V4 May19	May19
2.29 Implementation guidance of SA eCTD M1 specification v2.1	V1.2	Apr17
2.30 Biosimilars	V3 Aug14	Aug14
2.31 Fixed Dose Combination Products for HIV/Aids, Tuberculosis,	V2 Jul12	Aug12
2.32 Wound Dressings	V1 Nov11	V1 Nov11
2.33 Adverse Drug Reactions reporting post-marketing	V5 Jun17	Jun17
2.35 Labelling of medicines containing sugars	V1 Nov15	Dec15
2.36 Scheduling of medicines	V1 Jun14	Jun14
2.37 Scheduling of substances for prescribing by authorised prescribers	V1 Mar14	Mar14
2.38 SI International metric system	V3 Mar19	Mar19
2.39 Biological Medicines Pre-registration Consultation Meeting	V1 Jun14	Nar15
2.40 Multiple Applications of the same application with different proprietary names	V3 Nov03	Dec03
2.41 Emergency Procedures for Clinical Trial Sites	V2 Jun16	Oct16
2.42 Post Clinical Trial Drug Access for comment	V1 May18	Jun18
2.43 Oversight and Monitoring in Clinical Trials	V1 Sep16	Nov16
2.44 Cultivation of Cannabis and Manufacture of Cannabis-Related Pharmaceutical Products for Medicinal and Research Purposes	V2 Sep17	Nov17
2.45 Borderline Products for comment	V1 Feb17	Mar17
2.46 Co-packaging of medicines – for comment		
2.47 Clinical Trial Investigators	V2 Apr17	May17
2.48 Exemptions – for comment	V1 Nov17	Dec17
2.49 Capacity building & transformation in clinical trials research – for comment	V1 Nov17	Mar18
2.50 Medicines & Human Reproduction – for comment	V1 Nov17	May18
2.51 TIE Compensation Model	V1 May18	Jun18
2.52 Section 21 Access to Unregistered Medicines – for comment	V1 Dec17	Apr19
2.53 Investigator workload in clinical trials – for comment	V1 Apr19	May19
2.54 Quality of medicines used in clinical trials in South Africa – for comment	V1 May19	May19
3 Veterinary Medicines		
3.01 General information for Veterinary medicines	V1 Jan04	Jan 04
3.03 Bioavailability and bioequivalence	V1 Jan04	Jan04
3.04 Efficacy of and GCP for veterinary medicines	V1 Jun03	Jun03
3.05 Pre-clinical safety for veterinary medicines	V1 Jan04	Jan04
3.06 Efficacy of veterinary biological medicines	V1 Jan04	Jan04
3.07 Maximum residue limits and withdrawal periods	V1 jan04	V1 Jan04



3.08	Safety of veterinary biological medicines	V1 Jan04	Jan04
3.09	Reporting of adverse drug reactions	V1 Jan04	Jan04
3.10	Recall of veterinary medicines	V1 Jan04	Jan04
3.11	Completing section 21 application form	V1 Jan04	Jan04
3.12	Veterinary Orphan Products- <i>for comment</i>	V1 Aug11	May12
3.13	Veterinary Antimastitis Medicines	V1 Jun13	Nov13
4 Good Manufacturing Practice (GMP)*			
4.01	SA guide to Good manufacturing Practice (GMP)	V6 Dec17	Dec17
4.02	SA Guide to Good Wholesaling Practice + <i>amended for comment</i>	V2 Nov15	Jul16
4.03	Aerosol manufacturing	V1 Jun03	Jun03
4.04	Isolator technology	V1 Jun03	Jun03
4.05	Cephalosporin manufacture	V1 Jun03	Jun03
4.06	Penicillin manufacture	V1 Jun03	Jun03
4.07	Radiopharmaceutical manufacture	V1 Jun03	Jun03
4.08	Site master file	V2 Jun03	Oct10
4.09	Inspections involving GMP Inspectors	V1 Jul06	Jul06
4.10	Exporting of medicines by Wholesalers	V1.1 Oct15	May16
	SA GCP guidelines	DoH 2 nd Ed	Apr14
5 Miscellaneous			
5.01	Importation and exportation of medicines*	V1.1 May03	Jun11
5.02	Parallel importation of medicines (PIM) *	V1 Jun03	Jun03
5.03	Annual returns: international control*	V1 May03	
5.05	Destruction of schedule 5 medicines*	V1 May03	May03
5.06	Destruction of schedule 6 medicines*	V1 May03	May03
5.07	Recalls	V3 Dec08	Dec08
5.07	Recall / withdrawal of medicines, medical devices and IVDs - <i>for comment</i>	V5 Aug15	Sep15
5.08	Donations*	V2 May03	Sep10
5.09	Lodging a complaint on a medicine	V1.1 Aug06	Jun10
6 Forms			
6.01	MRF1 Medicine Registration Application (Human) - <i>replaced by ZA-CTD</i>	V1 Dec03	Dec03
6.02	MRF2 Screening of Application*		
6.03	MRF4 Package Insert Amendments*	V1 May03	V1 May03
6.04	ARF1 Adverse Drug Reaction Reporting	V4 Jul16	Apr17
6.05	CTF1 Clinical Trial Application	V3 May18	Jun18
6.06	CTF2 Clinical Trial Protocol Amendments	V1 May03	May03
6.07	CTF3 Clinical Trial Investigators and Sites Amendments	V1 May03	May03
6.08	VMRF1 Veterinary Medicine Registration	V1 May03	May03
6.09	PIF1 Parallel Importation Amendments	V1 Jun03	Jun03



6.10 Licence application to manufacture, import or export*	V2 Feb04	Mar09
6.11 Licence application to act as wholesaler or distributor**	V2 Feb04	Mar09
6.12 Section 21 Application form	V2 Jun17	Aug17
6.13 Guideline comments form	V2 Feb19	Apr19
6.14 Application for the Donation of Medicine to South Africa	V2 May03	Sep10
6.15 Screening Template for New Applications for Registration	V1 Jun14	Aug14
6.16 Validation Template for eCTD	V2 Sep16	Nov16
6.17 Licence application for Wholesaler to export	V1 Apr16	Apr16
6.18 Screening Template For new Applications CM	V1 Apr19	May19
6.19a FPP record sheet	V1 Aug16	Aug16
6.19b API record sheet	V1 Aug16	Aug16
6.20 Pre-registration Consultation Meeting Check-list	V1 Jun14	Mar15
6.21 Licence application to manufacture, import, distribute or export medical devices	V1 Jul16	Nov16
6.22 Licence application to import, distribute or export medical devices	V1.2 Jul16	Nov16
6.23 Template for comments on regulations	V1 Feb17	Feb17
6.24 Licence application to wholesale medical devices and IVDs	V1 Apr17	May17
6.25 Licence application to cultivate, manufacture or import Cannabis for medicinal purposes	V1 Sep17	Nov17
6.26 Licence application to wholesale medical devices v2	V2 Nov17	Dec17
6.27 CT Six monthly progress report form	V2 May18	Jun18
6.28 Valproate Annual Risk Acknowledgement Form	V1 Dec18	Dec18
Module 1.2.1 Application Form for ZA-CTD	V6May19	May19
ZA-CTD Application for registration of a medicine	V6 May19	May19
7 Complementary Medicines (CAMs)		
7.01 Complementary Medicines –Quality, Safety, and Efficacy	V3 Jun16	Jun16
7.02 Roadmap for Complementary Medicines	V1 Dec13	Dec13
7.03 CAMs Use of ZACTD format in preparation of registration application	V3 Jun16	Jun16
7.04 Health Supplements – Safety and Efficacy	V2 Jun16	Jun16
7.05 Complementary Medicines Registration Application ZA-CTD – Quality	V1 Jun16	Jun16
7.06 Complementary Medicines – Caffeine and Menthol – <i>for comment</i>	V2 Jun18	Aug18
Government Gazette 38133 Vitamins and Minerals		
8 Medical Devices and <i>In Vitro</i> Diagnostics		
8.01 General Information – Medical Devices and IVDs	V1 Nov17	Dec17
8.02 Medical Devices and IVDs Essential Principles – <i>for comment</i>	V1 Jul16	Jul16
8.03 Medical Devices and IVDs – Conformity Assessment Procedures – <i>for comment</i>	V1 Aug15	Sep18



8.04 Adverse event and post-marketing vigilance reporting of medical devices and IVDs – <i>for comment</i>	V2 Apr17	Ug17
8.05 Classification of medical devices and IVDs	V2 Apr17	Jul17
8.06 Access to and control of medical devices and IVDs – <i>for comment</i>		
8.07 Medical Device Quality Manual - <i>for comment</i>	V2 Jun17	Aug17
8.08 Medical device IVD technical dossier – <i>for comment</i>	V1 Jun17	Aug17
8.09 Medical device non-IVD technical dossier – <i>for comment</i>	V1 Jun17	Aug17
8.10 Questions & Answers: Licensing of Medical Device Establishment	V1 Nov17	Dec17
ZA CH1.04: Administrative Information – Application form – Application for registration of a Medical Device – <i>for comment</i>		
9 Communication with Industry / All Stakeholders		
9.01 Registration of antiretroviral medicines		
9.07 ADR terminology used in package inserts		
9.08 Dear Healthcare Professional Letter (DHCPL) and Medicines Safety Alerts (MSA) for comment	V3-1 Aug14	Mar15
9.13 Urgent Safety Restriction Notification (USRN)	V1 May06	Jun06
9.15 Regulation of Complementary Medicines		
9.16 Scheduling matters		
9.17 Meeting dates 2017		
9.22 Scheduling Matters - Accessibility of Malaria Prophylaxis Medicines	V1 Mar09	Mar09
9.24 Screening Aug09		
9.25 Enoxaparin Dec08	V1Dec08	Aug09
9.28 Cancellation or withdrawal	V1 Oct01	Sep09
9.33 Payments made to the Registrar of Medicines	V1 Nov10	Nov10
9.38 Implementation of CTD	V1 Jun11	Jun11
9.40 Changes during the Registration Process	V1 Jun11	Jun11
9.41 Important Medicine safety Information – withdrawal of dextropropoxyphene-containing medicines	V1 Sep11	Oct11
9.42 Safety-related Package Insert Notification (SR-PINs) Submission Dates for Pilot Phase	V1 Nov12	Nov12
9.46 eCTD Pilot Phase	V1 Dec13	Jan14
9.49 Scheduling of Meprobamate - <i>for comment</i>	V1 Dec13	Dec13
9.52 Audit of clinical package insert amendments	V1 Dec13	Jan14
9.53 Clinical Trial Committee meeting and submission dates	V1 Dec18	Dec18
9.55 Scheduling of Codeine		
9.56 Correction Notice to GG38133 on vitamins and minerals of Nov 2014	V1 Nov14	Nov14
9.57 Process for implementation of amended Regulations 9 and 10 of Nov 2014	V1 Nov14	Dec14
9.59 Electronic submission of clinical trial documents	V19 Apr19	Apr19
9.61 Scheduling of Aspirin		



9.65 Proposal to amend scheduling of codeine and dihydrocodeine - <i>for comment</i>	V1 Aug15	Aug15
9.66 Rejections and Comments on rejection		
9.68 Scheduling of Ibogaine		
9.69 Rescheduling of Diclofenac	V2 Sep16	Oct16
9.71 Expression of interest - API full assessment pilot		
9.72 Communication to industry Right of sale: Complementary medicines, GG Notice R.8709.72_Complementary_medicines_right_to_sale_Apr16_v1.docx April2016 Page 1 of 4 MEDICINES CONTROL COUNCIL PUBLICATION OF COMPLEMENTARY MEDICINES (CATEGORY D) SUBMITTED FOR REGISTRATION IN TERMS OF SECTION 14(3) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)	V1 Apr16	
9.73 Rescheduling of ephedrine, ephedra alkaloids and phenylpropanolamine	V2 Sep 16	Oct16
9.74 ZA CTD implementation		
9.75 Expression of interest - Pilot for electronic submission of ADR reports		
9.77 Backlog action plan		
9.78 Position statement: Status of Disinfectants, Antiseptics and Germicides		
9.79 Medical Device Establishments: Licence requirements	V1 Sep16	Sep16
9.80 eCTD Go-live in South Africa		
9.81 Workshop re expression of interest on API full assessment pilot		
9.82 Rescheduling of acetylcysteine	V1.1 Sep16	Oct16
9.83 Workshop re clinical trial related matters		
9.84 Clinical Trial Investigators	V2 Apr17	May17
9.85 Clarification of process to obtain a licence to grow cannabis for use as a medicine		
9.86 2.33 Post-marketing reporting of ADRs to human medicines in South Africa v4.1		
9.87 Complementary medicines - Licence application to manufacture and/or wholesale		
9.89 MCC wishes to appoint technical evaluators of applications for registration of complementary medicines		Jun17
9.91 Clinical Trials Workshop	Invitation	May19
9.92 Rescheduling of albendazole		
9.93 Scheduling matters - Regulatory status of cetylpyridinium chloride containing products		
9.94 Post-Importation Testing Workshop		Jun17
9.95 Medical Device Workshop		
9.97 Rescheduling of diclofenac	V1 Jun17	Jul17
9.96 Transitional arrangements for medical devices		Jul17
9.98 Meeting between the chief executive officers (CEOs) of pharmaceutical industry, the Chairperson of the Medicines Control Council and the Registrar of Medicines	Invitation	Aug17



9.99 Rescheduling of cannabidiol	V2 Jun17	Aug17
9.100 Indian Walnut		
9.101 Communication with Council or Committees		
9.102 MCC wishes to appoint quality and bioequivalence evaluators of applications for registration of medicines		
9.103 Tissue Engineering Products		
9.104 Rescheduling of Atovaquone & Proguanil		Dec17
9.105 Section 21 authorisation of sale of unregistered medical devices	V1 Sep17	Dec17
9.106 Position statement: Class A Medical Devices	V1 Sep17	Dec17
9.107 Medical Device Workshop	Invitation	Jan18
9.108 Meeting with CEOs	Invitation	Mar18
9.109 Meeting with Medical Device CEOs		
9.110 Meeting with Complementary Medicines CEOs	Invitation	May18
9.111 Rescheduling of Ibuprofen	V1 Apr18	Jun18
9.112 Rescheduling of Orphenadrine	V1 Apr18	Jun18
9.113 Submission Procedure for Section 21 Re-authorisations		Oct18
9.114 Submission of Pharmacovigilance Correspondence during protest action	V1 Sep18	Sep18
9.115 Submission of Type B Pharmaceutical Amendments during protest action	V1 Sep18	Sep18
9.116 Update about ongoing work of SAHPRA during interim closure of Civitas building	V1 Oct18	Oct18
9.117 Backlog clearance programme	V1 Nov 18	Nov18
9.118 Rescheduling of hyoscine butylbromide		Dec18
9.119 Medical Devices – Extension of Section 36 Exemption Sections 18A and 18B	V1 Dec18	Dec18
9.120 Interim Relocation of SAHPRA to CSIR	Notice	Jan19
9.121 Passing away of Lesiba Moshiga	Notice	Jan19
9.122 Status of Cannabis-containing products and the cultivation for medicinal use	V1 Jan19	Feb19
Industry Task Group meeting minutes Nov 2014 (revised Dec 2014), March 2015, June 2015, March 2016		
10 Media Releases		
10.04 Nevirapine 28/07/2003		Jul03
10.07 Withdrawal of rosiglitazone-containing medicines from the South African (SA) market	Press release	Jul11
10.08 High Court Judgment on Adcock Ingram's DPP-Containing Medicines	Press release	Nov11
10.09 The Safety of Cough and Cold Medicines in Children	Press release	Jun12
10.10 Registration of Complementary Medicines	Press release	Jan14



10.11 Medicines Control Council approves fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for pre-exposure prophylaxis of HIV	Press Release	
10.12 MCC warns against use of the unregistered medicine, Miracle Mineral Solution (MMS) and similar products for the treatment of medical conditions	Press release	May16
10.13 MCC alerts the public to the risks and harm associated with the inappropriate and non-prescribed use of testosterone-containing medicines	Press release	Aug16
10.14 MCC clarifies access to Cannabis for the treatment of medical conditions	Press release	Nov16
10.15 Use of Dolutegravir in pregnancy	Press release	May18
10.16 Public warned to avoid the purchase of medicines on-line	Press release	Jul18
10.17 Warning on safe use of NSAIDs	Press release	Jul18
10.18 Valsartan	Press release	Jul18
10.19 Press release – On-going work during protest action in Civitas Building, Pretoria	Press release	Aug18
10.20 Press release – New measures to minimise the risk of valproate use in pregnancy	Press release	Dec18
10.21 Press release – Side-effects associated with the use of quinolone and fluoroquinolone antibiotics	Press release	Dec18
10.22 Media Release – Reassurance on the safety of valsartan-containing medicines registered in South Africa	Press release	Dec18
10.23 Media Release – SAHPRA to issue cultivation licences for medicinal cannabis	Press release	Apr29
Withdrawal of VIOXX (rofecoxib) from the South African market		
PICs press release Paris 2014	Press release	
PICs press release Rome 2014	Press release	
PICs press release Geneva 2015	Press release	Jun15
12 Notification of Registration		
12.12 – 12.102	Multiple	
16 Licensing*		
16.01 Licence to manufacture, import or export	V1 Feb04	Feb04
16.02 Licence to act as wholesaler or distributor	V1 Feb04	V1 Feb04



16.03 Guideline for licence to manufacture, import, export or distribute medical devices and IVDs	V1 Jul16	Sep16
16.04 Licence to act as a wholesaler of medical devices & IVDs		
17 Fees		
17.02 Bank Details	V3 Nov18	Nov18
17.03 Retention Fees registration of human and veterinary medicines, and licences	V1 Jun18	Jun18
17.04 Fees for Complementary Medicines - <i>for comment</i>	V1 Nov13	Nov13
9.33 Payments made to the Registrar of Medicines		
Fees payable Government Gazette 39154 notice 784 01 September 2015		Sep15
Fees payable Government Gazette 42474 notice 647 24 May 2019		May19
18 Exemptions		
18.01 Exemptions in terms of Section 36 of Act 101 – Aug 2005	V1 Aug05	Aug05